



## In the United States Patent and Trademark Office

Applicants: Rosann M. Kaylor et al. Docket No.: 18264  
Serial No.: 10/736,662 Group:  
Confirmation No.: Not Received Examiner:  
Filed: December 16, 2003  
For: Detection of Premature Rupture of the Amniotic Membrane

### Information Disclosure Statement Pursuant to 37 C.F.R. 1.97(b) Before First Office Action or Within Three Months of Filing Date

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. 1.56 and in accordance with 37 C.F.R. 1.97 et seq., Applicants, through and by their attorneys, hereby wish to direct the Examiner's attention to the documents listed on the modified PTO 1449 Form. A copy of each non-U.S. patent document listed on the form is also presented herewith for the Examiner's review and convenience. Cited U.S. patents and U.S. patent application publications are not included in accordance with the U.S. Patent Office waiver of the requirement under 37 C.F.R. 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003.

By inclusion of any given document in this Information Disclosure Statement, Applicants in no way admit that such document is effective as prior art against the above-identified application under either 35 U.S.C. 102 or 35 U.S.C. 103.

Additionally, submission of any document is not to be taken as an admission of the materiality of the document to the prosecution of the present application.

The Examiner is requested to review each cited document and personally determine its prior art status.

Applicants recommend that the Examiner conduct an independent search for any and all available material prior art and independently review the results of such search and the documents cited within this Statement.



## List of Patents and Publications for Information Disclosure Statement

Applicant(s): Rosann M. Kaylor et al. Docket 18264  
 Serial No.: 10/736,662 Group:  
 Filed: December 16, 2003 Examiner:

U.S. PATENT DOCUMENTS							
Initials	Doc. No.	Date	Name	Class	Subclass	Filing Date	
A1	4,357,945	11/9/1982	Janko				
A2	5,096,830	3/17/1992	Senyei et al.				
A3	5,284,749	2/8/1994	Cowley et al.				
A4	5,554,504	9/10/1996	Rutanen				
A5	5,597,700	1/28/1997	Konstantinov et al.				
A6	5,698,404	12/16/1997	Strauss, III et al.				
A7	5,783,396	7/21/1998	Voroteliak et al.				
A8	5,856,196	1/5/1999	Alvarez et al.				
A9	6,126,597	10/3/2000	Smith et al.				
A10	6,149,590	11/21/2000	Smith et al.				
A11	6,206,840	3/27/2001	Abraham-Fuchs et al.				
Foreign Patent Documents							
Initials	Doc. No.	Date	Country	Class	Subclass	Trans.	
A1	0230343 A2	7/29/1987	EP			Yes	No
A2	0565541 B1	12/10/1997	EP				
A3	0612520 A2	8/31/1994	EP				
A4	WO 90/10061	9/7/1990	WO-PCT				
A5	WO 97/02018	1/23/1997	WO-PCT				
Other Documents							
Initials	Author, Title, Date, Pages, etc.						
A1	Geyer, V.H., "Die Herkunft der Furchtwasser-Enzyme", <u>Z. Klin. Chem.</u> , 8, 145, 1970, pp. 145-148.						
A2	Southren, A.L. et al., "Diamine oxidase activity in human maternal and fetal plasma and tissues at parturition", <u>Journal of Applied Physiology</u> , Vol. 20, 1965, pp. 1048-1051.						
A3	Butterworth, J. et al., "Lysosomal enzymes of amniotic fluid in relation to gestational age", <u>American Journal of Obstetrics and Gynecology</u> , Vol. 119, July 1974, pp. 821-828.						
A4	<u>Clinical Guide to Laboratory Tests</u> , 3 <sup>rd</sup> Edition, 1995, ed. Norbert W. Tietz, ISBN 0-7216-5035-X, Section 1-General Clinical Tests, pp. 46-50.						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with your next communication.

Examiner:

Date Considered:

Form PTO-1449 (Modified)

\* A2 and A5 - did not receive it

Applicants request the Examiner, in accordance with 37 C.F.R. 1.97, to indicate and make of record receipt and review of all of these documents by initialing the appropriate box in the accompanying PTO-1449. Applicants request that the undersigned receive a copy of the initialed PTO-1449.

If the Examiner refuses to consider any or all of the herein listed materials because it is the Examiner's opinion that this Information Disclosure Statement is not in compliance with 37 C.F.R. 1.97, Applicants respectfully request that the Examiner notify the undersigned, in writing, as to the basis of such opinion.

Please charge any prosecutorial fees which are due to Kimberly-Clark Worldwide, Inc. deposit account number 11-0875.

The undersigned may be reached at: (770) 587-7273.

Respectfully submitted,

ROSANN M. KAYLOR ET AL.


By: 

James B. Robinson

Registration No.: 34,912

CERTIFICATE OF MAILING

I, James B. Robinson, hereby certify that on March 23, 2004 this document is being deposited with the United States Postal Service as first-class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: 

James B. Robinson